They are not related.

We're proudly supporting BrainShield, a student-led initiative making a real impact in our community by providing high-quality helmets to underfunded schools!!

💥 So far:
$3,870 raised; 30 helmets donated; 65 amazing donors
🙏🙏 to everyone who’s supported! 💛

Join us: www.gofundme.com/f/helmets-fo...

Faculty dinner @kidneycon.bsky.social! For those who missed:

Topics covered 😉
Metabolic changes when Emperor Penguins molt
How a lion’s kidney handles protein load after it eats a kudu
Best baseball movies
Kidney disease in athletes
Genetically engineered crops
Politics & Academia

Absolutely Taylor! I am with you on the aspect of patient voice. Will review the points in the article. We were looking at it from purely a scientific perspective since there’s a lot of discrepancy in the literature that has affected patient care & research in the field.

For that reason, the proposal was not to remove the name aHUS altogether. I think the physicians, patients and pharma need to come together as a next step to make sure everyone’s interests are aligned without compromising scientific advancement.

However I also see how this can be from a pt’s perspective when they have been diagnosed with a certain disease and now unsure what to call it. Moreover, since the drugs are approved for “aHUS”, it has created some unrest.

With advancements in understanding of etiology & ongoing understanding of the role of complement in various TMAs, it is important to move to a more etiology based classification so that appropriate & timely t/t is available to those who need it and avoid unnecessary treatment in patients who don’t.

Similarly, aHUS was a term given to a disease when it was not HUS. So it describes what it is NOT rather than what it IS.

From a scientific standpoint yes absolutely it is a step in the right direction. This is similar to why C3G is not called MPGN anymore. We still struggle with the term FSGS because we don’t understand the etiology fully. We have called diseases by what is seen on the biopsy.

Congrats to @danieljdrucker.bsky.social for the. Breakthrough prize of 2025!

www.prnewswire.com/news-release...

(With Joel Habener, Jens Juul Holst, Lotte Bjerre Knudsen and Svetlana Mojsov for GLP1RAs)

#MedSky

Resistance-Based Muscle Therapy, Frailty, and Muscle Biopsy Findings in Kidney Transplant Candidates: A Clinical Trial

The @nytimes.com with @danagoldstein.bsky.social cover the story of Dr Rasha Alawieh being deported despite the Judge’s order (gift link)

(She’s a nephrologist, not a surgeon, but that doesn’t matter here)

www.nytimes.com/2025/03/16/u...

Wow!!

Missed the NephJC:(:(.
That’s a gorgeous mug!! Where did you get it?

📢 SCM25 speakers! Let your network know you're presenting at SCM25 by sharing this graphic!

Reshare with your session details and help spread the word. Tag @NKF_NephPros and use #NKFClinicals!

🔗 Learn more about SCM25: bit.ly/4hdIliU

#Nephrology #MedEd

For all coffee lovers and for those who (like me) wonder why we still have daylight savings time 😊🤷‍♀️

This week (and tonight on #NephJC) we are discussing the REGENCY trial on #obinutuzumab in SLE specifically #lupus nephritis

summary from
@sayalibthakare.bsky.social
@dramiliflores.bsky.social & @nephroseeker.medsky.social

www.nephjc.com/news/regency...

#lupuschat #NephSky #RheumSky

On the #AJKDBlog, revisit these interviews with:
- Drs. Gaddy, Murugapandian, @amyaimei.bsky.social on viral nephropathy
-Dr. Anuja Java discusses benefits of clinical genetic testing
-Drs. Nair, Liu, @rasheedahall.bsky.social on frailty measurements

bit.ly/3ztk4VV (FREE)

Fantastic overview of the latest in APOL-1 kidney disease by @genetickidneydoc.bsky.social @glomcon.org today!!

Highlighted work from various labs @gbadegesinlab.bsky.social.

Happy #NephMadness Day!

The 8 regions of #NephMadness 2025 have been revealed on the #AJKDBlog. If you're a #NephMadnessNewbie, we explain everything here: buff.ly/DCZDRfN

Looking forward to the fun and learning with all of you!

Counting down the Top Ten #NephMadness region posts from 2020-2024:

5️⃣ Thrombotic Microangiopathy Region (2023) https://bit.ly/3ERRvV2

Expert: @anuja_java
Writer: @viral_nephro @AkbarNouman
Exec: @KidneyWars @Maximal_Change

Teams: Primary TMA vs Secondary TMA

Our review on Post-Transplant TMA is out in JASN!

In this series, we outline pathophysiologic mechanisms of TMA & diagnostic workflow.

🙏 @rajmehrotra.bsky.social & #DavidEllison
for invitation & fabulous co-authors @nephrosparks.bsky.social & #DavidKavanagh

journals.lww.com/jasn/abstrac...

Nice piece and fully agree!!

Interesting read

www.nytimes.com/2025/02/17/o... ( #GiftLink)

We should not minimize the pain experience

#Medsky